

Paola Villa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4550560/publications.pdf>

Version: 2024-02-01

47
papers

902
citations

567144

15
h-index

501076

28
g-index

47
all docs

47
docs citations

47
times ranked

1068
citing authors

#	ARTICLE	IF	CITATIONS
1	Hormone replacement therapy and cervical cancer: a systematic review of the literature. <i>Climacteric</i> , 2021, 24, 120-127.	1.1	21
2	Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. <i>Gynecological Endocrinology</i> , 2020, 36, 535-539.	0.7	7
3	No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). <i>Maturitas</i> , 2020, 142, 38-44.	1.0	26
4	Recent Insights on the Maternal Microbiota: Impact on Pregnancy Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 528202.	2.2	64
5	Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?. <i>Maturitas</i> , 2020, 138, 76-77.	1.0	16
6	Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. <i>Supportive Care in Cancer</i> , 2020, 28, 2507-2512.	1.0	9
7	The interplay between immune system and microbiota in gynecological diseases: a narrative review. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 5676-5690.	0.5	13
8	Cardiovascular Risk/Benefit Profile of MHT. <i>Medicina (Lithuania)</i> , 2019, 55, 571.	0.8	8
9	Fertility preservation in chemo-radiotherapy for rectal cancer: A combined approach. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 77-79.	0.9	7
10	Approach to sexual dysfunction in women with cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 630-634.	1.2	33
11	Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 609-618.	1.8	11
12	Menopausia y Terapia Hormonal de la Menopausia Las recomendaciones 2018 de la Unidad de Endocrinología Ginecológica de Clínica Alemana de Santiago -Sociedad Italiana de la Menopausia y la Sociedad Chilena de Endocrinología Ginecológica. <i>Revista Chilena De Obstetricia Y Ginecologia</i> , 2018, 83, 527-550.	0.1	3
13	Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society. <i>Minerva Obstetrics and Gynecology</i> , 2018, 70, 27-34.	0.5	11
14	The impact of combined nutraceutical supplementation on quality of life and metabolic changes during the menopausal transition: a pilot randomized trial. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 791-801.	0.8	14
15	Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 370-380.	0.5	8
16	Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. <i>Menopause</i> , 2016, 23, 33-39.	0.8	14
17	Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. <i>Maturitas</i> , 2016, 83, 40-44.	1.0	151
18	A non-invasive prevention program model for the assessment of osteoporosis in the early postmenopausal period: a pilot study on FRAX® and QUS tools advantages. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 191-198.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women. <i>Journal of Obstetrics and Gynaecology</i> , 2015, 35, 835-838.	0.4	11
20	Ovarian volume and gluco€insulinaemic markers in the diagnosis of <sc>PCOS</sc> during adolescence. <i>Clinical Endocrinology</i> , 2013, 78, 285-290.	1.2	25
21	Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. <i>Gynecological Endocrinology</i> , 2013, 29, 678-682.	0.7	7
22	Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 92-6.	1.8	4
23	Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2011, 95, 158-163.	0.5	21
24	The Differential Effect of the Phytoestrogen Genistein on Cardiovascular Risk Factors in Postmenopausal Women: Relationship with the Metabolic Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 552-558.	1.8	93
25	Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase. <i>Fertility and Sterility</i> , 2009, 91, 1857-1863.	0.5	11
26	Fasting and Post-methionine Homocysteine Levels in Alzheimer's Disease and Vascular Dementia. <i>International Journal for Vitamin and Nutrition Research</i> , 2009, 79, 166-172.	0.6	14
27	The Differential Effect of the Phytoestrogen Genistein on Cardiovascular Risk Factors in Postmenopausal Women: Relationship With the Metabolic Status. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 523-524.	0.2	0
28	Estro-progestin supplementation enhances the growth hormone secretory responsiveness to ghrelin infusion in postmenopausal women. <i>Fertility and Sterility</i> , 2008, 89, 398-403.	0.5	15
29	Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. <i>Climacteric</i> , 2008, 11, 498-508.	1.1	16
30	Hyperhomocysteinemia and cardiovascular risk in postmenopausal women: the role of folate supplementation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 130-5.	1.4	9
31	I-Folic Acid Supplementation in Healthy Postmenopausal Women: Effect on Homocysteine and Glycolipid Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4622-4629.	1.8	42
32	Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 305-305.	3.8	12
33	Which Treatment Options Should Be Used in Adolescents with Polycystic Ovary Syndrome?. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2004, 17, 705-10.	0.4	4
34	Effect of gonadotropin-releasing hormone agonist treatment on growth hormone responses in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2004, 82, 250-252.	0.5	0
35	Insulin and GH secretion in adolescent girls with irregular cycles: Polycystic vs multifollicular ovaries. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 305-311.	1.8	9
36	Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 547-550.	1.8	14

#	ARTICLE	IF	CITATIONS
37	Effect of the opioid blockade on the feeding-induced growth hormone response to growth hormone-releasing hormone in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2002, 78, 994-1000.	0.5	3
38	Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism. <i>Human Reproduction</i> , 2001, 16, 430-434.	0.4	11
39	Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. <i>Fertility and Sterility</i> , 1999, 71, 115-121.	0.5	18
40	Influence of chronic naltrexone treatment on growth hormone secretion in normal subjects. <i>European Journal of Endocrinology</i> , 1997, 137, 631-634.	1.9	5
41	Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 538-543.	1.5	8
42	Endocrinology: The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. <i>Human Reproduction</i> , 1995, 10, 1653-1657.	0.4	36
43	Effect of corticotropin-releasing factor on the pituitary-ovary axis in human luteal phase. <i>Gynecological Endocrinology</i> , 1995, 9, 271-276.	0.7	2
44	Effect of naltrexone treatment on the treadmill exercise-induced hormone release in amenorrheic women. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 839-847.	1.8	11
45	Postpartum thyroid dysfunction in an Italian population residing in an area of mild iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 669-674.	1.8	37
46	Circulating immune complexes in serum and in cerebrospinal fluid of patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1988, 77, 373-381.	1.0	13
47	Effects of cadmium on platelet thromboxane and vascular prostacyclin production. <i>Toxicology and Applied Pharmacology</i> , 1982, 65, 185-188.	1.3	25